1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

13 Jun 2024
Admin
News Article

Maruho Introduces Mitchga SC Injection 30mg Vials

Maruho introduces Mitchga SC injection 30mg vials, an antibody treatment for pruritus associated with atopic dermatitis (paediatric) and prurigo nodularis in Japan

Overview

Maruho Co., Ltd. announces that it has launched Mitchga subcutaneous (SC) injection 30mg vials (Japanese Accepted Name (JAN): Nemolizumab (genetical recombination), in Japan for the treatment of the following diseases only when existing treatment is insufficiently effective: pruritus associated with atopic dermatitis (children aged =6 and <13 years), prurigo nodularis (adults and children aged =13 years).

Nemolizumab Subcutaneous Injection

The product is a vial for subcutaneous injection containing nemolizumab, a humanized anti- interleukin-31 (IL-31) receptor A monoclonal antibody discovered and developed by Chugai Pharmaceutical Co., Ltd., as an active ingredient.
In September 2016, Maruho entered into a license agreement with Chugai to develop and market the product in the skin disease area for the Japanese market.
• Maruho developed the product in Japan and acquired approval for manufacturing and marketing in March 2024, followed by the NHI drug price listing in May 2024, leading to the launch of the product.

About IL-31

IL-31 is a cytokine that induces itch and is involved in the development of pruritus caused by atopic dermatitis.
It has also been shown to induce itch in prurigo nodularis and to be involved in its pathogenesis.
By competitively inhibiting the binding of IL-31 to its receptor, this product is expected to improve the pruritus and skin symptoms associated with atopic dermatitis (paediatric patients) and prurigo nodularis, thereby improving patients' Quality of Life (QOL).

Maruho Acquisition

In March 2022, Maruho acquired the world's first manufacturing and marketing approval for ""Mitchga subcutaneous injection 60mg syringes"" for the treatment of pruritus associated with atopic dermatitis in adults and children over 13 years old (only when existing treatment is insufficiently effective) in Japan. Maruho launched ""Mitchga subcutaneous injection 60mg syringes"" in August 2022 in Japan.

Maruho Efforts for Treatment

Maruho, specializing in dermatology, is committed to contributing to the smiles of patients suffering from itching caused by atopic dermatitis and patients suffering from prurigo nodularis by promoting the appropriate use of the product and ""Mitchga subcutaneous injection 60mg syringes."

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!